Answers are grounded in this paper and cite their sources.
The present short review summarizes and updates clinical experience with two classes of drugs introduced for the management of type 2 diabetes mellitus over the past 8 years: (i) the glucagon-like peptide-1 receptor agonists; and (ii) the dipeptidyl peptidase 4 inhibitors. Both classes of agents address the so called "incretin defect" in patients with T2DM.
No takes yet. Share an insight, caveat, or question.
George Grunberger (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: